Navigation Links
Lorus Therapeutics Announces Publication of a Clinical Study Demonstrating Encouraging Results with LOR-2040 in Combination with Cytarabine in Patients with Acute Myeloid Leukemia (AML)
Date:7/2/2008

y us are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance, or achievements that may be expressed or implied by such forward-looking statements, including, among others: our ability to obtain the capital required for research and operations, the inherent risks in early stage drug development including demonstrating efficacy, development time/cost and the regulatory approval process; the progress of our clinical trials; our ability to find and enter into agreements with potential partners; our ability to attract and retain key personnel; changing market conditions; and other risks detailed from time-to-time in our ongoing quarterly filings, annual information forms, annual reports and annual filings with Canadian securities regulators and the United States Securities and Exchange Commission.

Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the section entitled "Risk Factors" in our Annual Information Form underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this press release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by law. We cannot assure you that such statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Investors are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein.

Lorus Therapeutics Inc.'s recent press releases are available through th
'/>"/>

SOURCE Lorus Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Lorus Advances Clinical Development of GTI-2040 Combined with Ara-C in Acute Myeloid Leukemia
2. Lorus Therapeutics Appoints Peter Korth as Chief Financial Officer
3. Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin(R)
4. Lorus Therapeutics presents new findings for the anticancer drugs LOR-253 and LOR-2040
5. Lorus initiates development program exploring novel route of administration for LOR-2040
6. Lorus Therapeutics Strengthens Its Senior Management Team Through Internal Promotions
7. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
8. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
9. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
10. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
11. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... JH Technologies announces the ... Irvine. JH Technologies, a leader in sales and ... an expanded partnership with Leica Microsystems into the Southern ... analysis solutions will be featured at the grand opening ... showroom facility is located within the JH Technologies office’s ...
(Date:9/17/2014)... 17, 2014 Terracon Corporation has announced ... TerraPure tank . This addition to the company’s ... FDA-compliant linear polyethylene and available in 125 or 250 ... ships in two weeks or less. , The new ... found in Terracon’s existing TerraPure tank line – plus ...
(Date:9/17/2014)... 17, 2014 Alternative Fuels Americas, Inc. (AFAI) announced ... Special Purpose Vehicle in partnership with Jatro Greentech, Inc., a ... company. The SPV shall be called AFAI Jatro Green Ethiopia ... majority shareholder. The SPV shall pursue Jatropha planting and biofuels ... Ethiopia . "Although we have ...
(Date:9/17/2014)... RXi Pharmaceuticals Corporation (NASDAQ: ... developing and commercializing innovative therapies addressing major unmet ... has been granted a patent by the United ... delivery system for delivering its "original" RNAi compounds ... treatment of diseases with an inflammatory component. Potential ...
Breaking Biology Technology:JH Technologies displays newest microscope imaging technology at Southern California showroom grand opening 2JH Technologies displays newest microscope imaging technology at Southern California showroom grand opening 3Terracon Introduces Pre-Engineered TerraPure® Tank for Ultrapure Water Applications 2AFAI Signs Joint Venture Agreement With Jatro Greentech Inc. 2AFAI Signs Joint Venture Agreement With Jatro Greentech Inc. 3RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 2RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 3RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 4
... The world,s smallest chess board about the diameter ... were winners in this year,s design contest for, respectively, ... National Laboratories in mid May. The two winning ... facility, one of the most advanced in the world. ...
... Corgenix Medical Corporation (OTC Bulletin Board: CONX), a worldwide developer ... its AspirinWorks® Test June 17-19 at the Pri-Med New York ... Convention Center in New York, N.Y. , ... Corgenix representatives will be on-hand during the conference ...
... New data from a retrospective cohort study showed that up ... (GID) that can have a substantial adverse effect on major PD-related clinical ... Congress of Parkinson,s Disease and Movement Disorders in Buenos Aires, Argentina ... , , ...
Cached Biology Technology:Texas Tech, U of Utah win Sandia microdevice competition 2Texas Tech, U of Utah win Sandia microdevice competition 3Texas Tech, U of Utah win Sandia microdevice competition 4Corgenix to Exhibit AspirinWorks(R) Test at Pri-Med New York 2Corgenix to Exhibit AspirinWorks(R) Test at Pri-Med New York 3New Study Showed the Impact of Gastrointestinal Disorders in Patients With Parkinson's Disease 2New Study Showed the Impact of Gastrointestinal Disorders in Patients With Parkinson's Disease 3New Study Showed the Impact of Gastrointestinal Disorders in Patients With Parkinson's Disease 4
(Date:9/16/2014)... have discovered the "molecular brakes" that time the generation ... mice. These "hair cells" translate sound waves into electrical ... interpreted as sounds. If the arrangement of the cells ... of the research will be published in The ... proteins Hey1 and Hey2 act as brakes to prevent ...
(Date:9/16/2014)... inherit certain traits from our parents that are pre-determined. ... play out by taking certain drugs or better yet, ... team of researchers at the Boston University School of ... research. , Epigenetics regulates gene expression in a ... which prevent permanent mutations or alterations within the gene ...
(Date:9/16/2014)... species has its own bacterial identity. That,s the conclusion ... institutions who studied the genetic fingerprints of bacteria on ... , "This study demonstrates for the first time that ... ecological strategies possess very different microbial communities on their ... postdoctoral researcher in the UO,s Institute of Ecology and ...
Breaking Biology News(10 mins):Hey1 and Hey2 ensure inner ear 'hair cells' are made at the right time, in the right place 2Epigenetic drugs: A hope to treat cancer resistance and reduce cancer relapse? 2Epigenetic drugs: A hope to treat cancer resistance and reduce cancer relapse? 3Microbiome research shows each tree species has a unique bacterial identity 2
... Future of the Nuclear Industry" will be the Plenary Session topic ... taking place June 28-July 1, 2010, at the Salt Palace Convention ... Chair of the Nuclear Regulatory Commission, will be the lead presenter ... Over 250 presentations between June 28 and July 1 will occur ...
... been established for more than 50 years as one ... termed bipolar disorder. However, scientists have never been ... new research from Cardiff University scientists suggests a possible ... better understanding of the illness and potentially more effective ...
... bacteria lead oil companies to change their methods of harvesting ... reducing the carbon dioxide that burning oil and gasoline discharges ... Larter, professor of geoscience and holder of the ... Calgary, was the keynote speaker today for the 2010 Goldschmidt ...
Cached Biology News:55th annual meeting of the Health Physics Society 2
...
...
... The pCITE-2a-c(+) vectors are designed for enhanced translation ... extracts, e.g. rabbit reticulocyte lysate. The maps for ... with the following exceptions: pCITE-2b(+) is a 3793 ... BstX I and Xcm I sites. Subtract 7 ...
...
Biology Products: